Level 2

- Short term management tachycardia and hypertension in a monitored patient
- For SVT termination

- No intrinsic sympathomimetic activity or membrane stabilising properties

only available as an IV formulation.
presented as a clear liquid usually at a concentration of 10mg/ml

It produces
decreases in heart rate and cardiac output and myocardial oxygen consumption

- Care with: Opioids, Halo, OAD, CCB

- It is an irritant to veins and may lead to tissue necrosis with extravasation

bioavailabilty Only available as IV therefore 100%

lipid solubility is high so it crosses the BBB

60% to albumin

3.5 L/Kg

neither hepatic or renal!
by red blood cell esterases to a mostly inactive metabolite

urine

10 minutes

Beta Blocker

Cardio-selective beta blocker with rapid onset and offset.

Beta blockage leads to ↓Gs activity in receptor associated organs and
associated ↓in adenylyl cyclase and intracellular Ca2+.

IV
dose In 10mg increments titrate to effect

Antiarrhythmic –
Vaughan Williams Class II
Beta blocker

Cardio-selective beta blocker with rapid onset and off-set.

Beta blockage leads to ↓ Gs activity in receptor associated organs and
associated ↓ in adenylyl cyclase and intracellular Ca2+.

neither hepatic or renal! by red blood cell esterases to a mostly inactive metabolite

IV
dose In 10mg increments titrate to eff¬ect